Related Experiment Video
Updated: Jan 30, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
[Zhenwu Decoction delays ventricular hypertrophy in rats with uremic cardiomyopathy]
Jun Lai1, Yingzhi Wu1, Liwei Hang1
1Department of Cardiology, Heart Center, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
Insights
Zhenwu Decoction effectively reduces indoxyl sulfate levels and inhibits ventricular hypertrophy in rats with uremic cardiomyopathy, delaying adverse cardiac remodeling. This study highlights its therapeutic potential for kidney disease-related heart conditions.
Area of Science:
- Cardiovascular Research
- Nephrology
- Traditional Chinese Medicine
Background:
- Uremic cardiomyopathy is a significant complication of chronic kidney disease.
- Elevated indoxyl sulfate (IS) levels contribute to cardiac hypertrophy and dysfunction in uremia.
- Ventricular hypertrophy is a key factor in the progression of uremic cardiomyopathy.
Purpose of the Study:
- To evaluate the inhibitory effects of Zhenwu Decoction on ventricular hypertrophy in a rat model of uremic cardiomyopathy.
- To elucidate the underlying mechanisms by which Zhenwu Decoction exerts its cardioprotective effects.
Main Methods:
- In vitro: Rat cardiomyocytes were treated with IS to assess protein synthesis and expression.
- In vivo: A rat model of uremic cardiomyopathy was established via 5/6 nephrectomy.
- Treatment groups received varying doses of Zhenwu Decoction; biochemical and histological analyses were performed.
Main Results:
- IS exposure increased protein synthesis and BNP, p-ERK1/2, and p-p38 expression in cardiomyocytes.
- Uremic rats exhibited elevated serum creatinine, BUN, 24-h urine protein, IS, and cardiac mass indexes.
- Zhenwu Decoction treatment significantly reduced IS levels and attenuated ventricular hypertrophy, downregulating myocardial BNP, p-ERK1/2, p-38, and p-JNK expression.
Conclusions:
- Zhenwu Decoction effectively lowers plasma IS levels in rats with uremic cardiomyopathy.
- The treatment inhibits ventricular hypertrophy, suggesting a role in delaying ventricular remodeling.
- These findings support Zhenwu Decoction as a potential therapeutic agent for uremic cardiomyopathy.
Objective:
To investigate the inhibitory effect of Zhenwu Decoction on ventricular hypertrophy in rats with uremic cardiomyopathy and explore the mechanism.
Methods:
Cardiocytes isolated from suckling rats were divided into control group and indoxyl sulfate (IS) group, and the protein synthesis was assayed with [3H]- leucine incorporation and cellular protein expressions were detected using Western blotting. Fifty SD rats were randomly divided into sham operation group, model group, and low- and high-dose Zhenwu Decoction treatment groups, and except for those in the sham operation group, all the rats underwent 5/6 nephrectomy. Four weeks after the operation, the rats in low- and high-dose treatment groups were given Zhenwu Decoction via gavage at the dose of 4.5 g/kg and 13.5 g/kg, respectively; the rats in the sham-operated and model groups were given an equal volume of distilled water. After 4 weeks of treatment, serum levels of IS were determined, and cardiac and ventricular mass indexes were measured in the rats; cardiac ultrasound was performed and Western blotting was used to measure the expressions of BNP, p-ERK1/2, p-p38 and p-JNK in the myocardium.
Results:
Rat cardiomyocytes treated with IS showed significantly enhanced protein synthesis and increased expression levels of BNP, p-erk1/2, and p-p38 as compared with the control cells (P < 0.01), but the expression of p-jnk was comparable between the two groups. In the animal experiment, the rats in the model group showed significantly increased serum creatinine (SCr) and urea nitrogen (BUN) levels, 24-h urine protein (24 hUpro), plasma IS level, left ventricular mass index (LVMI) and whole heart mass index (HMI) compared with those in the sham group (P < 0.01); Both LVESD and LVEDD were significantly reduced and LVAWS, LVAWD, LVPWS and LVPWD were significantly increased in the model rat, which also presented with obvious cardiomyocyte hypertrophy and increased myocardial expressions of BNP, p-ERK1/2, p-p38 and p-jnk (P < 0.01). Compared with the rats in the model group, the rats treated with low-dose and high-dose Zhenwu Decoction had significantly lowered levels of SCr, BUN, 24 hUpro and IS (P < 0.05) and decreased LVMI and HMI; LVESD, LVEDD, LVPWS, LVAWS, and LVAWD were improved more obviously in the high-dose group, and the myocardial expressions of BNP, p-ERK1/2, p-p38 and p-JNK was significantly downregulated after the treatment.
Conclusions:
Zhenwu Decoctin can reduce plasma IS levels and inhibit ventricular hypertrophy to delay ventricular remodeling in rats with uremic cardiomyopathy.
More Related Videos
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy VI: Nursing Management

